Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution

被引:18
|
作者
Sher, David J. [1 ]
Liptay, Michael J. [2 ]
Fidler, Mary Jo [3 ]
机构
[1] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Cardiothorac Surg, Chicago, IL 60612 USA
[3] Rush Univ, Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 89卷 / 02期
关键词
RANDOMIZED-TRIAL; PHASE-II; PREOPERATIVE CHEMOTHERAPY; RACIAL-DIFFERENCES; RADIATION-THERAPY; ONCOLOGY-GROUP; RADIOTHERAPY; SURGERY; CHEMORADIATION; CARCINOMA;
D O I
10.1016/j.ijrobp.2014.01.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The optimal locoregional therapy for stage IIIA non-small cell lung cancer (NSCLC) is controversial, with definitive chemoradiation therapy (CRT) and neoadjuvant therapy followed by surgery (NT-S) serving as competing strategies. In this study, we used the National Cancer Database to determine the prevalence and predictors of NT in a large, modern cohort of patients. Methods and Materials: Patients with stage IIIA NSCLC treated with CRT or NT-S between 2003 and 2010 at programs accredited by the Commission on Cancer were included. Predictors were categorized as clinical, time/geographic, socioeconomic, and institutional. In accord with the National Cancer Database, institutions were classified as academic/research program and as comprehensive and noncomprehensive community cancer centers. Logistic regression and random effects multilevel logistic regression were performed for univariable and multivariable analyses, respectively. Results: The cohort consisted of 18,581 patients, 3,087 (16.6%) of whom underwent NT-S (10.6% induction CRT, 6% induction chemotherapy). The prevalence of NT-S was constant over time, but there were significant relative 31% and 30% decreases in pneumonectomy and right-sided pneumonectomy, respectively, over time (P trend <.02). In addition to younger age, lower T stage, and favorable comorbidity score, indicators of higher socioeconomic status were strong independent predictors of NT-S, including white race, higher income, and private/managed insurance. The type of institution (academic/research program vs comprehensive or noncomprehensive community cancer centers, odds ratio 1.54 and 2.08, respectively) strongly predicted NT-S, but treatment volume did not. Conclusions: Neoadjuvant therapy followed by surgery was an uncommon treatment approach in Commission on Cancer programs, and the prevalence of postinduction pneumonectomy decreased over time. Higher socioeconomic status and treatment at academic institutions were significant predictors of NT-S. Further research should be performed to enable a better understanding of these disparities. (C) 2014 Elsevier Inc.
引用
收藏
页码:303 / 312
页数:10
相关论文
共 50 条
  • [1] Pneumonectomy for Clinical Stage IIIA Non-Small Cell Lung Cancer: The Effect of Neoadjuvant Therapy
    Broderick, Stephen R.
    Patel, Aalok P.
    Crabtree, Traves D.
    Bell, Jennifer M.
    Morgansztern, Daniel
    Robinson, Clifford G.
    Kreisel, Daniel
    Krupnick, A. Sasha
    Patterson, G. Alexander
    Meyers, Bryan F.
    Puri, Varun
    ANNALS OF THORACIC SURGERY, 2016, 101 (02) : 451 - 458
  • [2] The prognosis of clinical stage IIIa non-small cell lung cancer in Taiwan
    Cheng, Ya-Fu
    Huang, Jing-Yang
    Lin, Ching-Hsiung
    Wang, Bing-Yen
    CANCER MEDICINE, 2023, 12 (16): : 17087 - 17097
  • [3] Adjuvant Chemotherapy Improves Survival in pN-positive Clinical Stage IIIA Non-Small Cell Lung Cancer After Neoadjuvant Therapy and Resection
    Atay, Scott M.
    Amini, Maziar
    Ding, Li
    David, Elizabeth A.
    Mcfadden, P. Michael
    Wightman, Sean C.
    Kim, Anthony W.
    ANNALS OF THORACIC SURGERY, 2021, 112 (01) : 197 - 205
  • [4] Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands
    Joosten, Pieter J. M.
    Damhuis, Ronald A. M.
    van Diessen, Judi N. A.
    de Langen, Joop A.
    Belderbos, Jose S. A.
    Smit, Egbert F.
    Klomp, Houke M.
    Veenhof, Alexander A. F. A.
    Hartemink, Koen J.
    ACTA ONCOLOGICA, 2020, 59 (07) : 748 - 752
  • [5] Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
    Shin, Sumin
    Kim, Hong Kwan
    Cho, Jong Ho
    Choi, Yong Soo
    Kim, Kwhanmien
    Kim, Jhingook
    Zo, Jae Ill
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Park, Keunchil
    Pyo, Hongryull
    Ahn, Yong Chan
    Shim, Young Mog
    JOURNAL OF THORACIC DISEASE, 2020, 12 (05) : 2602 - 2613
  • [6] Optimal Surgical Timing After Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer
    Rice, Jonathan D.
    Heidel, Justin
    Trivedi, Jaimin R.
    van Berkel, Victor H.
    ANNALS OF THORACIC SURGERY, 2020, 109 (03) : 842 - 847
  • [7] Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer
    Watanabe, Shun-ichi
    Nakagawa, Kazuo
    Suzuki, Kenji
    Takamochi, Kazuya
    Ito, Hiroyuki
    Okami, Jiro
    Aokage, Keiju
    Saji, Hisashi
    Yoshioka, Hiroshige
    Zenke, Yoshitaka
    Aoki, Tadashi
    Tsutani, Yasuhiro
    Okada, Morihito
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (12) : 1112 - 1118
  • [8] Neoadjuvant Chemoradiotherapy for Stage iii Non-Small Cell Lung Cancer
    Sher, David J.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [9] Stage IIIA Non-Small Cell Lung Cancer Treatment and Outcomes: A Single Institution Retrospective Analysis
    Duan, Richard
    Kwan, Michelle
    Kordon, Avram
    Hu, Carolyn J.
    Vanjani, Nisheka
    Liu, Yingzhe
    Thomas, Tarita O.
    Gupta, Divya
    Patel, Jyoti
    Yadav, Poonam
    Abazeed, Mohamed E.
    Sun, Zequn
    Gharzai, Laila A.
    THORACIC CANCER, 2025, 16 (03)
  • [10] Treatment of resectable stage IIIA non-small cell lung cancer
    Cardenal, Felipe
    Palmero, Ramon
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 13 - 15